[Federal Register Volume 88, Number 105 (Thursday, June 1, 2023)]
[Notices]
[Pages 35876-35877]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-11656]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality


Notice of Meeting

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) 
announces a Special Emphasis Panel

[[Page 35877]]

(SEP) meeting on ``Diagnostic Safety in Ambulatory Care.'' This SEP 
meeting will be closed to the public.

DATES: July 26-27, 2023.

ADDRESSES: Agency for Healthcare Research and Quality (Video Assisted 
Review), 5600 Fishers Lane, Rockville, Maryland 20857.

FOR FURTHER INFORMATION CONTACT: Jenny Griffith, Committee Management 
Officer, Office of Extramural Research, Education and Priority 
Populations, Agency for Healthcare Research and Quality, (AHRQ), 5600 
Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 427-1557.

SUPPLEMENTARY INFORMATION: A Special Emphasis Panel is a group of 
experts in fields related to health care research who are invited by 
AHRQ, and agree to be available, to conduct on an as needed basis, 
scientific reviews of applications for AHRQ support. Individual members 
of the Panel do not attend regularly scheduled meetings and do not 
serve for fixed terms or a long period of time. Rather, they are asked 
to participate in a particular review meeting which require their type 
of expertise.
    The SEP meeting referenced above will be closed to the public in 
accordance with the provisions set forth in 5 U.S.C. 1009(d), 5 U.S.C. 
552b(c)(4), and 5 U.S.C. 552b(c)(6). Grant applications for 
``Diagnostic Safety in Ambulatory Care'' are to be reviewed and 
discussed at this meeting. The grant applications and the discussions 
could disclose confidential trade secrets or commercial property such 
as patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.
    Agenda items for this meeting are subject to change as priorities 
dictate.

    Dated: May 26, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023-11656 Filed 5-31-23; 8:45 am]
BILLING CODE 4160-90-P